Journal
NATURE GENETICS
Volume 50, Issue 6, Pages 783-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41588-018-0118-8
Keywords
-
Categories
Funding
- US National Institutes of Health (NIH) [R01HG007538, R01CA193466, U54CA217297]
- Cancer Prevention Research Institute of Texas (CPRIT) grant [RP150292]
- CPRIT [RP100107, RP140800]
- Welch Foundation [AU-1889]
- NIH [RO1GM046454]
- Houston Endowment, Inc.
Ask authors/readers for more resources
Widespread mRNA 3' UTR shortening through alternative polyadenylation(1) promotes tumor growth in vivo(2). A prevailing hypothesis is that it induces proto-oncogene expression in cis through escaping microRNA-mediated repression. Here we report a surprising enrichment of 3' UTR shortening among transcripts that are predicted to act as competingendogenous RNAs (ceRNAs) for tumor-suppressor genes. Our model-based analysis of the trans effect of 3' UTR shortening (MAT3UTR) reveals a significant role in altering ceRNA expression. MAT3UTR predicts many trans-targets of 3' UTR shortening, including PTEN, a crucial tumor-suppressor gene(3) involved in ceRNA crosstalk(4) with nine 3' UTRshortening genes, including EPS15 and NFIA. Knockdown of NUDT21, a master 3' UTR-shortening regulator(2), represses tumor-suppressor genes such as PHF6 and LARP1 in trans in a miRNA-dependent manner. Together, the results of our analysis suggest a major role of 3' UTR shortening in repressing tumor-suppressor genes in trans by disrupting ceRNA crosstalk, rather than inducing proto-oncogenes in cis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available